Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05263427
Other study ID # 2021_0548
Secondary ID 2022-A00107-36AN
Status Recruiting
Phase N/A
First received
Last updated
Start date August 31, 2022
Est. completion date August 2024

Study information

Verified date February 2022
Source University Hospital, Lille
Contact Charles Garabedian, MD,PhD
Phone 0320445962
Email charles.garabedian@chru-lille.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

During a previous clinical trial (RCF-abdo: 2018-A01194-51), trans-abdominal signals were collected in 90 patients at the maternity Jeanne de Flandre. This database allowed us to develop a new medical device able to measure in real time and continuously the fetal heart rate and the uterine contractions. The goal here is to assess the performance of the device in real situation during labour. This study will be carried out in the maternity labor ward in CHU Lille, France. The TOCONAUTE will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph. For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Pregnant woman in labor - Singleton - Cephalic presentation Exclusion Criteria: - Hospitalisation for a medical termination of pregnancy - Death in utero - Multiple pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TOCONAUTE
This study will be carried out during delivery. The will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph. For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient.

Locations

Country Name City State
France Hop Jeanne de Flandre Chu Lille Lille

Sponsors (4)

Lead Sponsor Collaborator
University Hospital, Lille BioSerenity, Clinical Investigation Centre for Innovative Technology Network, National Research Agency, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fetal heart rate with the TOCONAUTE The fetal heart rate from the our device will be averaged on 3 beats and resampled at 4Hz to be comparable to the fetal heart rate from the cardiotocograph.
Both of the signals will be resynchronized and compared sample by sample with a Pearson's correlation test.
Measure of the fetal heart rate with the TOCONAUTE compared to the measure of the fetal heart rate with a cardiotocograph.
1 year
Secondary Uterine contractions with the TOCONAUTE according to the different phase of labor. Measure of the uterine contractions with the TOCONAUTE compared to the measure of the uterine contractions with a cardiotocograph according to the different phase of labor.
Both signals of the uterine contractions will be resynchronized and compared sample by sample with a Pearson's correlation test.
1 year
Secondary Maternal heart rate with the TOCONAUTE Measure of the maternal heart rate with the TOCONAUTE compared to the measure of the maternal heart rate with a cardiotocograph.
Both signals of the maternal heart rate will be resynchronized and compared sample by sample with a Pearson's correlation test.
1 year
Secondary Fetal heart rate with the TOCONAUTE according to the different phase of labor. Measure of the fetal heart rate with the TOCONAUTE compared to the measure of the fetal heart rate with a cardiotocograph according to the different phase of labor. 1 year
Secondary Fetal stress index (Heart rate variability index reflecting parasympathetic fluctuation) Feasibility of the measure of the Fetal stress index (Heart rate variability index reflecting parasympathetic fluctuation) 1 year
See also
  Status Clinical Trial Phase
Completed NCT03364491 - Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Phase 3
Recruiting NCT03487185 - Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy N/A